Compugen (NASDAQ:CGEN) Price Target Lowered to $4.00 at Truist Financial

Compugen (NASDAQ:CGEN) had its price objective trimmed by Truist Financial from $5.00 to $4.00 in a research report sent to investors on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Separately, StockNews.com lowered shares of Compugen from a buy rating to a hold rating in a report on Monday, May 13th.

Compugen Stock Up 7.5 %

Shares of NASDAQ:CGEN opened at $2.44 on Tuesday. Compugen has a 12 month low of $0.53 and a 12 month high of $3.03. The company’s 50-day moving average price is $2.21 and its two-hundred day moving average price is $1.89. The firm has a market cap of $211.35 million, a P/E ratio of -12.84 and a beta of 2.72.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings data on Tuesday, March 5th. The biotechnology company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.01. The company had revenue of $33.46 million for the quarter, compared to the consensus estimate of $60.00 million. As a group, equities analysts predict that Compugen will post 0.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CGEN. Kingsview Wealth Management LLC bought a new position in shares of Compugen in the 3rd quarter valued at about $78,000. Tocqueville Asset Management L.P. bought a new position in shares of Compugen in the 3rd quarter valued at about $71,000. Silverarc Capital Management LLC boosted its stake in shares of Compugen by 6.1% in the 3rd quarter. Silverarc Capital Management LLC now owns 350,188 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Heron Bay Capital Management acquired a new stake in shares of Compugen in the 1st quarter valued at approximately $32,000. Institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.